Compared with cisplatin treatment, tumor-infiltrating CD4+, CD8+ T cells, and CD11c+ DCs in the lung tissues rose significantly in HS-Pt-CDs+690 nm treated groups with proportions of 1.8%, 8.8%, and 18.7%, respectively (Fig. 6i, j, and Supplementary Figs. S42, S43). Here, ITGAX is linked to neoplasm.